Introduction
Pulmonary arterial hypertension (PAH) is clinically defined as a mean pulmonary arterial pressure (PAP) of ≥25 mmHg at rest with a normal pulmonary capillary wedge pressure (PCWP) (1) (2) (3) (4) . The pathophysiology of PAH is characterized by progressively increasing pulmonary vascular resistance (PVR) and right ventricular heart failure in terms of insufficient oxygen supply of the right ventricle, which causes limitations in the performance of daily life activities and exercise intolerance with dyspnea and fatigue symptoms (4, 5) .
The New York Heart Association (NYHA) classification reflects disease severity and prognosis associated with worsening symptoms during ordinary physical activity and functional capacity in patients with PAH (6) . Additionally, one of the most feasible methods for noninvasively grading the severity of exercise limitation and assessing disease symptoms in PAH is the evaluation of resting and exercise haemodynamics by both submaximal and maximal exercise test measurements (7) (8) (9) (10) . Cardiopulmonary exercise testing (CPET) for the evaluation of disease severity is important to assess peak oxygen consumption (VO 2peak ), metabolic equivalents, and maximal workload during exercise tests, as well as the minute ventilationto-carbon dioxide output (V E -V CO2 ) slope (7, 8) . Paolillo et al. demonstrated a reduction in VO 2peak and remarked on the prognostic value of the elevated V E -V CO2 slope in patients with PAH (4). The V E -V CO2 slope reflects disease severity, and it has been shown that there is a correlation between the V E -V CO2 slope and NYHA functional class (9) . However, the 6-min walk test (6MWT) is commonly used in PAH patients as a submaximal exercise test to indicate the exercise capacity of patients who cannot tolerate the maximal incremental test, despite the fact that CPET has more clinical significance in terms of prognostic value and evaluation of disease severity (11, 12) . Although the distance walked in the 6MWT is significantly shorter among PAH patients than in age-and sex-matched healthy control subjects, it does not evaluate the resting hemodynamics, the response of the cardiopulmonary system, or the functional gas exchange (7, 13) . Furthermore, there are no studies in the literature that demonstrate the prognostic value of the 6MWT for the NYHA classification in PAH patients.
Limited data exist concerning the relation between the 6MWT and incremental CPET in patients with PAH. Thus, the aims of the present study were to assess the relation between the distance walked during the 6MWT and exercise capacity as determined by CPET in patients with PAH and to investigate the prognostic value of the 6MWT in comparison with the clinical parameters of CPET and echocardiography findings.
Materials and methods

Study subjects
This study included 30 patients with PAH (including chronic thromboembolic pulmonary hypertension, CTEPH) who were followed regularly in the pulmonary arterial hypertension outpatient clinic of our cardiology department. Among the patients, 5 (16.7%) had connective tissue disease, 10 (33.3%) had congenital heart disease, 2 (6.7%) had CTEPH, and 13 (43.3%) had idiopathic pulmonary arterial hypertension. One patient was classified as class I, 19 patients were in class II, and 10 patients were in class III according to the NYHA functional classification. All patients were treated with PAH-specific drugs, including bosentan, inhaled iloprost, sildenafil, or a combination of these drugs, in addition to other palliative treatments, such as furosemide, spironolactone, and digoxin, as needed. The diagnosis of PAH was based on right heart catheterization, with mean PAP >25 mmHg, PCWP <15 mmHg, and PVR >3 resistance units as defined by PAH guidelines (10) . Patients with severe heart failure, restrictive and obstructive pulmonary disease, and acute infection were excluded from the study. All patients completed the 6MWT and cardiopulmonary exercise testing when they were clinically stable during outpatient visits. The Dokuz Eylül University Medical Ethics Committee approved the study, and all patients provided written informed consent.
Measurements
Subject characteristics, including age, height, body weight, and NYHA classification with PAH etiology, were recorded. The patients' dyspnea status was evaluated using the four-item Modified Medical Research Council (MMRC) Dyspnea Scale (14) . Body mass index (BMI) was calculated as weight/height squared (expressed in kg/m 2 ).
Right heart catheterization
A diagnostic right heart catheterization to assess pulmonary and cardiac haemodynamics was performed in all patients while they were in a stable condition during hospitalization. Baseline hemodynamic variables and mean PAP were measured in all patients. Cardiac output (CO) was measured by Fick's method (15) . Total pulmonary resistance was calculated by dividing mean PAP by CO. Cardiac index (CI) was calculated by dividing CO by body surface area.
Six-minute walk test (6MWT)
The 6MWT was conducted for all patients according to a standardized protocol as described in the American Thoracic Society (ATS) guidelines (16) . Patients were instructed to walk along a 30-m corridor to cover as much ground as possible in 6 min. They were encouraged with standardized statements. The distance covered during the test, as well as dyspnea and fatigue symptoms, were evaluated.
Cardiopulmonary exercise testing (CPET)
All patients performed incremental cardiorespiratory exercise testing on a cycle ergometer. Gas exchange measurements (Oxycon Pro) were taken during the following events: 3 min of rest; 3 min of unloaded leg cycling for a warm-up followed by 3 min of progressively increasing the work rate up to 20 W; and 3 min of 20-W incremental work load. After that, work load was increased by 3 W every 12 s to maximum tolerance, and gas exchange measurements were recorded until maximal exertion. Pulse oximetry (SpO 2 ), heart rate (HR), 12-lead ECG, and blood pressure were monitored and recorded. Maximal work load and metabolic equivalent were recorded during the test. Ventilatory parameters (minute ventilation (V E ), O 2 uptake (VO 2 ), and CO 2 output (VCO 2 )) were interpreted by breath measurement at 6-s intervals. The anaerobic threshold (AT) percentage of O 2 uptake was calculated and minute ventilation-to-CO 2 output at AT was expressed as V E -VCO 2 @AT.
Statistical analysis
Statistical analysis was performed using the SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Analyses included frequency distribution, percentages, and calculation of means and related standard deviations (mean ± SD). Continuous variables, such as summary of demographics, resting hemodynamics, and CPET, were expressed as means and standard deviations. Frequency distributions of categorical variables and continuous variables were included as descriptive statistics. Relations between 6MWT distance and catheterization data and 6MWT distance and CPET data were analyzed for the 30 patients using the Pearson correlation test. Correlation coefficients between 6MWT distance and other variables were determined by linear regression analysis. The independent contributors to 6MWT that were entered into the analysis were CI and age variables. Differences between the two functional classes were analyzed by the Mann-Whitney U test.
Results
Most of the 30 PAH patients were middle-aged women (Table 1) in NYHA class II or III. Their dyspnea symptoms were mild (54.8%), moderate (22.6%), or severe (6.5%) according to the MMRC Dyspnea Scale.
At cardiac catheterization, all patients had increased resting pulmonary hypertension (mean PAP 82.58 ± 21.49 mmHg), increased PVR, and reduced CI ( Table 1 ).
All patients completed the 6MWT and CPET without incident. The duration of exercise testing in all patients averaged 9.4 (range: 3 to 15) min. The parameters of exercise gas exchange were systematically different in PAH patients. Average peak VO 2 was 12.78 ± 4.72 mL kg -1 min -1 with a peak respiratory exchange ratio of 0.97 ± 0.11, suggesting that the majority of subjects exercised close to their maximal capacity. There was a marked decrease in peak oxygen consumption and peak heart rate and an increase in minute ventilation-to-carbon dioxide output. The mean distance covered during the 6MWT was 404.75 ± 104.07 m (Table 1) . Table 2 summarizes multiple correlations between the 6MWT and other variables. Age was significantly negatively correlated with 6MWT distance. The exercise parameters of peak VO 2 , peak workload, and metabolic equivalents (METs) were strongly correlated with 6MWT. Additionally, CI was correlated with peak VO 2 and MET.
Correlations
Linear regression analysis revealed that age and CI were significant and independent predictors of performance in the 6MWT. These two variables accounted for 35.4% of the variance in the distance covered during the 6MWT (Table  3 ). The distance covered during the 6MWT was predicted by the following equation:
Distance (m) = 455.229 + (0.382 × cardiac index) -(0.494 × age). Table 4 displays the results of the NYHA gradations according to the severity of reduction in aerobic capacity. Moderate PAH patients had an end-exercise respiratory exchange ratio of 0.95 ± 0.98; severe PAH patients had a higher end-exercise respiratory exchange ratio (1.00 ± 0.12) compared with moderate PAH patients, indicating that the patients with PAH had developed significant metabolic acidosis and had exercised heavily. Using this method of grading disease severity, there was a statistically significant difference between the two groups in key parameters of aerobic function (peak VO 2 and MET) and distance walked in the 6MWT. The average distance covered was equivalent for subjects with moderate and severe PAH (426.05 ± 95.40 m versus 356.75 ± 89.94 m, respectively; P < 0.05) (Table 4) . Furthermore, pulmonary hemodynamic data regarding mean PAP and PVR were not statistically significantly different between the two groups.
Physiological severity of PAH
Discussion
In the present study, we found that 6MWT distance is severely affected in patients with PAH, and we also showed that CI and age were two significant determinants for exercise performance in terms of walking distance. These two factors accounted for 35.4% of the variance in the test. Furthermore, the distance walked in the 6MWT was significantly correlated with the following exercise parameters: peak VO 2 , workload, and MET. Additionally, CI was correlated with peak VO 2 and MET. Although there was an increase in the V E -V CO2 slope in PAH patients, there was no correlation between the other variables as a ventilatory response to the exercise test. The data between the two different NYHA classifications showed that 6MWT distance and VO 2peak statistically significantly decreased in proportion to the severity of NYHA functional class in patients with PAH.
We assessed functional exercise capacity using the 6MWT, which primarily evaluates pulmonary and cardiac impairments in patients with PAH. The self-paced 6MWT evaluates the global and integrated responses of all the systems involved during exercise (16) (17) (18) . It has been shown that the 6MWT test has prognostic value in disease severity and mortality by revealing decreased distance in patients with heart failure (19) . Additionally, it was previously shown by Miyamoto et al. that a 6MWT distance below 332 m is an indicator of poor prognosis in PAH (7) . The moderate and severe PAH patients in our study demonstrated 6MWT distances of 426.05 and 356.75 m, respectively; these distances were greater than expected according to their disease severity compared to the cut-off point of 332 m reported by Miyamoto et al. for poor prognosis in functional class II and III patients. Nearly all of the patients in our study walked farther than in that study (404.75 m).
Linear regression analysis in this study showed that a large portion of the variance in the 6MWT distance of the PAH patients was explained by age and CI. This finding revealed that higher age and lower CI values resulted in lower functional capacity in patients with PAH. In the literature, there is only one study, by Britto et al. (20) , reporting that the distance covered during the 6MWT is significantly associated with age and heart rate variability; in another study, Miyamoto et al. found that 6MWT distance is correlated with CO (6). However, there are no data concerning the relation between 6MWT distance and CI. In our study, CI was the first variable that explained the variance in 6MWT distance, indicating that lower CI was associated with shorter 6MWT distance or functional capacity. In addition, PAH patients in our study had a higher CI (over 2. . Age was the second variable that explained the variance in 6MWT distance in our study, indicating that older age was associated with shorter 6MWT NYHA = New York Heart Association, CPET = cardiopulmonary exercise testing, RER = respiratory exchange ratio, Peak VO 2 = peak oxygen consumption, V E -V CO2 @AT = minute ventilation-to-carbon dioxide output at anaerobic threshold, CI: cardiac index. Age ( Cardiac index = CI, Metabolic equivalent = MET, V E -V CO2 @AT = minute ventilation-to-carbon dioxide output at anaerobic threshold, Peak VO 2 = peak oxygen consumption, ** = statistically significant. distance. These results are consistent with those of Enright et al., who demonstrated that 6MWT distance is strongly associated with age and that elderly subjects had lower walking distances (18) .
In the present study, we first demonstrated that the distance walked in 6 min decreased in proportion to the decrease in peak VO 2 and MET determined by maximal CPET. Maximal CPET results showed that patients with PAH had reduced peak VO 2 values. Peak VO 2 assesses the subject's maximal work ability and maximal ability of the circulatory system to increase CO. In PAH, this relates to pulmonary vasculopathy, which limits blood flow through the lungs (7). On the other hand, 6MWT distance correlated modestly with VO 2peak , MET, and workload in the present study.
Additionally, considering the increased demand of ventilatory deficiency, the minute ventilation-to-carbon dioxide output slope increased in our PAH patients. Previously, it was shown that 6MWT distance was negatively correlated with VE-VCO 2 slope in patients with PAH (7). However, our findings did not show a similar correlation. Only the hemodynamic parameter of CI showed a statistically significant correlation with peak VO 2 . This result shows that decreased CI causes reduced oxygen consumption or functional capacity (21) .
Several authors reported a close association between 6MWT distance and maximal exercise testing in patients with heart failure, heart transplantation, and primary pulmonary hypertension (7, 22) . Our analysis showed that there were significant differences between the NYHA class II and class III patients in terms of 6MWT distance, peak VO 2 , and MET. Reduction and association among these variables reflect right ventricle dysfunction, reduced CI, and oxygen deficit during exercise (9) . Concerning the prognostic value of the submaximal 6MWT, it may be concluded that the 6MWT can be used as an equivalent to the peak VO 2 parameter of maximal exercise testing.
In conclusion, submaximal exercise testing can be used safely and easily to assess decreased functional capacity in patients with PAH. The 6MWT provides information that may be a better index for the patient's NYHA functional class determination than maximal exercise testing. The determination of walking distance by CI and age indicators enables patient-specific assessment of prognosis and disease severity.
